Effect on Weight Loss of Exenatide Versus Placebo

Exclusion Criteria

• •Are treated with any of the following excluded medications: \*exogenous insulin, thiazolidinedione, or alpha-glucosidase inhibitor for more than 1 week within 6 weeks of screening; \*Symlin injection at any time; \* Byetta injection within 3 months of screening or discontinuation of therapy at any time due to adverse reaction; \*drugs that directly affect gastrointestinal motility; \*use of a weight loss drug (including those available over the counter) within 3 months of screening; \*chronic (lasting longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of screening
• •Have conditions contraindicating metformin and/or sulfonylurea use
• •Have had a change in lipid-lowering agents within 6 weeks of screening
• •Have received glucagon-like peptide-1 (GLP-1) analogs, or dipeptidyl peptidase-IV inhibitors (DPP-IV inhibitors) or have previously participated in this study
• •Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry